Top

BMC Health Services Research

Published in:

Open Access 01-12-2022 | Research article

Drug repurposing: a systematic review on root causes, barriers and facilitators

Authors: Nithya Krishnamurthy, Alyssa A. Grimshaw, Sydney A. Axson, Sung Hee Choe, Jennifer E. Miller

Published in: BMC Health Services Research | Issue 1/2022

Abstract

Background

Repurposing is a drug development strategy receiving heightened attention after the Food and Drug Administration granted emergency use authorization of several repurposed drugs to treat Covid-19. There remain knowledge gaps on the root causes, facilitators and barriers for repurposing.

Method

This systematic review used controlled vocabulary and free text terms to search ABI/Informa, Academic Search Premier, Business Source Complete, Cochrane Library, EconLit, Google Scholar, Ovid Embase, Ovid Medline, Pubmed, Scopus, and Web of Science Core Collection databases for the characteristics, reasons and example of companies deprioritizing development of promising drugs and barriers, facilitators and examples of successful re-purposing.

Results

We identified 11,814 articles, screened 5,976 for relevance, found 437 eligible for full text review, 115 of which were included in full analysis. Most articles (66%, 76/115) discussed why promising drugs are abandoned, with lack of efficacy or superiority to other therapies (n = 59), strategic business reasons (n = 35), safety problems (n = 28), research design decisions (n = 12), the complex nature of a studied disease or drug (n = 7) and regulatory bodies requiring more information (n = 2) among top reasons. Key barriers to repurposing include inadequate resources (n = 42), trial data access and transparency around abandoned compounds (n = 20) and expertise (n = 11). Additional barriers include uncertainty about the value of repurposing (n = 13), liability risks (n = 5) and intellectual property (IP) challenges (n = 26). Facilitators include the ability to form multi-partner collaborations (n = 38), access to compound databases and database screening tools (n = 32), regulatory modifications (n = 5) and tax incentives (n = 2).

Conclusion

Promising drugs are commonly shelved due to insufficient efficacy or superiority to alternate therapies, poor market prospects, and industry consolidation. Inadequate resources and data access and challenges negotiating IP are key barriers to repurposing reaching its full potential as a core approach in drug development. Multi-partner collaborations and the availability and use of compound databases and tax incentives are key facilitators for repurposing. More research is needed on the current value of repurposing in drug development and how to better facilitate resources to support it, where valuable, especially financial, staffing for out-licensing shelved products, and legal expertise to negotiate IP agreements in multi-partner collaborations.

Trial registration

The protocol was registered on Open Science Framework (https://osf.io/f634k/) as it was not eligible for registration on PROSPERO as the review did not focus on a health-related outcome.

Available only for authorised users

Graul AI, Sorbera L, Pina P, Tell M, Cruces E, et al. Year’s New Drugs and Biologics – 2009. Drug News Perspect. 2010;23:7–36.PubMedCrossRef

Kesselheim AS, Tan YT, Avorn J. The roles of academia, rare diseases, and repurposing in the development of the most transformative drugs. Health Aff (Millwood). 2015;34(2):286–93.CrossRef

Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–83.PubMedCrossRef

Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829–42.PubMedPubMedCentralCrossRef

Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM, et al. Giving drugs a second chance: Overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol. 2017;7:273.PubMedPubMedCentralCrossRef

Deotarse PP, Jain AS, Baile MB, Kolhe NS, Kulkarni AA. Drug repositioning: a review. Int J Pharm Sci Rev. 2015;4(8):51–8.

Novack GD. Repurposing medications. Ocul Surf. 2021;19:336–40.PubMedCrossRef

Business Brief -- AGOURON PHARMACEUTICALS INC.: Pharmaceutical Firm Drops Experimental Cancer Drug. Wall Street Journal 1997 Dec 03:1-B10.

Mandrioli R, Mercolini L. Discontinued anxiolytic drugs (2009–2014). Expert Opin Investig Drugs. 2015;24(4):557–73.PubMedCrossRef

10.

Greil A. Pfizer Drops 2 Potential Drugs. Newswires. Wall street journal (Eastern ed). 2005. Available from: https://www.wsj.com/articles/SB112021359980775345. Accessed 20 Aug 2021.

11.

Powell B. Silence is not the best medicine: requiring disclosure of clinical trial data for abandoned drugs. J Leg Med (N Y). 2012;33(4):571–92.CrossRef

12.

Offit PA. Why are pharmaceutical companies gradually abandoning vaccines? Health Aff (Millwood). 2005;24(3):622–30.CrossRef

13.

Chesbrough H, Chen EL. Recovering abandoned compounds through expanded external IP licensing. Calif Manage Rev. 2013;55(4):83–101.CrossRef

14.

Novac N. Challenges and opportunities of drug repositioning. Trends Pharmacol Sci. 2013;34(5):267–72.PubMedCrossRef

15.

Mayor S. Cancer charity to re-examine shelved drugs. Lancet Oncol. 2006;7(7):534.PubMedCrossRef

16.

Tartaglia LA. Complementary new approaches enable repositioning of failed drug candidates. Expert Opin Investig Drugs. 2006;15(11):1295–8.PubMedCrossRef

17.

Roland D. AstraZeneca gives rejected drugs a second life. Wall Street journal (Eastern ed). 2017. Cited 20 Aug 2021. Available from: https://www.wsj.com/articles/astrazeneca-gives-rejected-drugs-a-second-life-1489402801.

18.

Crow D. J&J boss’s long quest ends with $30bn Actelion deal. Financial Times. 2017. Cited 20 Aug 2021. Available from: https://www.ft.com/content/ee3b4ae2-e3e6-11e6-8405-9e5580d6e5fb.

19.

Herschel M. Portfolio decisions in early development: Don’t throw out the baby with the bathwater. Pharmaceut Med. 2012;26(2):77–84.

20.

Roche Scraps Cholesterol Drug for Lack of Benefit. MondayMorning. 2012;20(20)1–1.1p.

21.

Pulley JM, Jerome RN, Shirey-Rice JK, Zaleski NM, Naylor HM, Pruijssers AJ, et al. Advocating for mutually beneficial access to shelved compounds. Future Med Chem. 2018;10(12):1395–8.PubMedCrossRef

22.

Grundy R, James I, Bountra C, Harrison T. Reconfiguring Drug Discovery Through Innovative Partnerships. Drug Discovery World. 2014. Available from: Cited 20 Aug 2021. https://www.ddw-online.com/reconfiguring-drug-discovery-through-innovative-partnerships-844-201410/.

23.

Langreth R, Cortez M. Confusing Alzheimer's data leaves moments decision in FDA hands. Bloomberg News. Bloomberg. 2019. Cited 20 Aug 2021. Available from: https://www.bloomberg.com/news/articles/2019-12-06/confusing-alzheimer-s-data-leaves-momentus-decision-in-fda-hands.

24.

Cortez M, Langreth R. Biogen resumes Alzheimer’s studies to offer controversial drug. Bloomberg News. Bloomberg. 2019. Cited 20 Aug 2021. Available from: https://www.bnnbloomberg.ca/biogen-resumes-alzheimer-s-studies-to-offer-controversial-drug-1.1358152.

25.

Kuchler H. Biogen shares soar on plan to seek Alzheimer’s drug approval. Financial Times. 2019. Cited 20 Aug 2021. Available from: https://www.ft.com/content/c48e12b2-f4bc-11e9-a79c-bc9acae3b654.

26.

Becker RE, Greig NH. Fire in the ashes: can failed Alzheimer’s disease drugs succeed with second chances? Alzheimers Dement. 2013;9(1):50–7.PubMedCrossRef

27.

Becker RE, Greig NH. Was phenserine a failure or were investigators mislead by methods? Curr Alzheimer Res. 2012;9(10):1174–81.PubMedPubMedCentralCrossRef

28.

Becker RE, Greig NH. Lost in translation: Neuropsychiatric drug development. Sci Transl Med. 2010;2(61):61rv6-61rv6.PubMedPubMedCentralCrossRef

29.

Hayes A, Nutt D. The European college of neuropsychopharmacology (ECNP) medicines chest initiative: Rationale and promise. Pharmaceut Med. 2015;29(5):269–73.

30.

Rogawski MA, Federoff HJ. Disclosure of clinical trial results when product development is abandoned. Sci Transl Med. 2011;3(102):102cm29.

31.

Biomedicine KJ. NIH’s secondhand shop for tried-and-tested drugs. Science. 2011;332(6037):1492.CrossRef

32.

Cha Y, Erez T, Reynolds IJ, Kumar D, Ross J, Koytiger G, et al. Drug repurposing from the perspective of pharmaceutical companies: Drug repurposing in pharmaceutical companies. Br J Pharmacol. 2018;175(2):168–80.PubMedCrossRef

33.

A collection of 68 deprioritized pharmaceutical compounds is being made available to academic researchers. Thepharmaletter.com. 2014. Available from: https://www.thepharmaletter.com/article/world-s-largest-collection-of-deprioritized-pharma-compounds-opens-to-researchers.

34.

Polamreddy P, Gattu N. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discov Today. 2019;24(3):789–95.PubMedCrossRef

35.

Feemster R. Gene Logic: Rescue squad [Internet]. Pharmaceutical Executive. 2006. Cited 20 Aug 2021. Available from: https://www.pharmexec.com/view/gene-logic-rescue-squad.

36.

Mullard A. Drug repurposing programmes get lift off. Nat Rev Drug Discov. 2012;11(7):505–6.PubMedCrossRef

37.

Mullard A. Bank tests drug development waters. Nat Rev Drug Discov. 2014;13(9):643–4.PubMedCrossRef

38.

Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534(7607):314–6.PubMedCrossRef

39.

Frail DE, Brady M, Escott KJ, Holt A, Sanganee HJ, Pangalos MN, et al. Pioneering government-sponsored drug repositioning collaborations: progress and learning. Nat Rev Drug Discov. 2015;14(12):833–41.PubMedCrossRef

40.

Hayes AG, Nutt DJ. Compound asset sharing initiatives between pharmaceutical companies, funding bodies, and academia: learnings and successes. Pharmacol Res Perspect. 2019;7(4):e00510.PubMedPubMedCentralCrossRef

41.

Fetro C, Scherman D. Drug repurposing in rare diseases: myths and reality. Therapie. 2020;75(2):157–60.PubMedCrossRef

42.

Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.PubMedCrossRef

43.

Katare PB, Banerjee SK. Repositioning of drugs in cardiometabolic disorders: Importance and current scenario. Curr Top Med Chem. 2016;16(19):2189–200.PubMedCrossRef

44.

Marusina K, Welsch DJ, Rose L, Brock D, Bahr N. The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning. Drug Discov Today Ther Strateg Winter. 2011;8(3–4):77–83.CrossRef

45.

Loging W, Rodriguez-Esteban R, Hill J, Freeman T, Miglietta J. Cheminformatic/bioinformatic analysis of large corporate databases: application to drug repurposing. Drug Discov Today Ther Strateg. 2011;8(3–4):109–16.CrossRef

46.

New indications and a sense of (re)purpose. EBioMedicine. 2015;2(10):1257–8.

47.

Wadman M. New cures sought from old drugs. Nature. 2012;490(7418):15.PubMedCrossRef

48.

Würth R, Thellung S, Bajetto A, Mazzanti M, Florio T, Barbieri F. Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. Drug Discov Today. 2016;21(1):190–9.PubMedCrossRef

49.

Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov. 2020;15(4):397–401.PubMedCrossRef

50.

Bisson WH. Drug repurposing in chemical genomics: can we learn from the past to improve the future? Curr Top Med Chem. 2012;12(17):1883–8.PubMedCrossRef

51.

Neuberger A, Oraiopoulos N, Drakeman DL. Renovation as innovation: is repurposing the future of drug discovery research? Drug Discov Today. 2019;24(1):1–3.PubMedCrossRef

52.

Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther. 2013;7:753–66.PubMedPubMedCentralCrossRef

53.

Wechsler J. Who will fund pharmaceutical R&D?. Applied Clinical Trials Online. 2011. Cited 20 Aug 2021. Available from: https://www.appliedclinicaltrialsonline.com/view/who-will-fund-pharmaceutical-rd.

54.

Bombelles T, Coaker H. Neglected tropical disease research: rethinking the drug discovery model. Future Med Chem. 2015;7(6):693–700.PubMedCrossRef

55.

Swamidass SJ. Mining small-molecule screens to repurpose drugs. Brief Bioinform. 2011;12(4):327–35.PubMedCrossRef

56.

Khaladkar M, Koscielny G, Hasan S, Agarwal P, Dunham I, Rajpal D, et al. Uncovering novel repositioning opportunities using the open targets platform. Drug Discov Today. 2017;22(12):1800–7.PubMedCrossRef

57.

Bellera CL, Alberca LN, Sbaraglini ML, Talevi A. In silico drug repositioning for Chagas disease. Curr Med Chem. 2020;27(5):662–75.PubMedCrossRef

58.

Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30(4):317–20.PubMedCrossRef

59.

Wang Y, Zeng J. Predicting drug-target interactions using restricted Boltzmann machines. Bioinformatics. 2013;29(13):i126–34.PubMedPubMedCentralCrossRef

60.

Shahreza M, Ghadiri N, Mousavi SR, Varshosaz J, Green JR. A review of network-based approaches to drug repositioning. Brief Bioinform. 2018;19(5):878–92.CrossRef

61.

Naylor S, Schonfeld M. Therapeutic Drug Repurposing, Repositioning and Rescue Part I: Overview. Drug Discovery World. 2014. Cited 20 Aug 2021. Available from: https://www.ddw-online.com/therapeutic-drug-repurposing-repositioning-and-rescue-part-i-overview-1463-201412/.

62.

Challener CA. Can Artificial Intelligence Take the Next Step for Drug Repositioning? Pharma Technol. 2018;42(9):22–5.

63.

Kim T-W. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer’s disease. Neurotherapeutics. 2015;12(1):132–42.PubMedCrossRef

64.

Williams R. Discontinued drugs in 2012: oncology drugs. Expert Opin Investig Drugs. 2013;22(12):1627–44.PubMedCrossRef

65.

Smith RB. Repositioned drugs: integrating intellectual property and regulatory strategies. Drug Discov Today Ther Strateg. 2011;8(3–4):131–7.CrossRef

66.

Collins FS. Mining for therapeutic gold. Nat Rev Drug Discov. 2011;10(6):397.PubMedPubMedCentralCrossRef

67.

Mehndiratta MM, Wadhai S, Tyagi B, Gulati N, Sinha M. Drug repositioning. Int J Epilepsy. 2016;03(02):091–4.CrossRef

68.

Pisanu C, Melis C, Squassina A. Lithium pharmacogenetics: where do we stand? Drug Dev Res. 2016;77(7):368–73.PubMedCrossRef

69.

Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8(2):135–55.PubMedPubMedCentralCrossRef

70.

Rach C, Lukas J, Müller R, Sendler M, Simon P, Salloch S. Involving Patient Groups in Drug Research: A Systematic Review of Reasons. Patient Prefer Adherence. 2020;14:587–97. https://doi.org/10.2147/PPA.S232499.CrossRefPubMedPubMedCentral

71.

Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: an overview and guidelines. Journal of Business Research. 2021;133:285–96 (in the manuscript and/or the response).CrossRef

72.

Jack A. AstraZeneca likely to abandon drug Pharmaceuticals: [London 1st Edition]. Financial Times. 2007;20:18.

73.

Lilly, rivals not backing away from pricey Alzheimer's studies. Indianapolis Business Journal. 2017;38(6):19.

74.

Auer K, Trachter R, Van den Bogaerde J, Bassaganya-Riera J, Sorrentino D. Translational research and efficacy of biologics in Crohn’s disease: a cautionary tale. Expert Rev Clin Immunol. 2014;10(2):219–29.PubMedCrossRef

75.

Bishop T. Repurposing companies experiment with unintended uses for pharmaceuticals. Knight Ridder Tribune Business News. 2005;20:1.

76.

Buonansegna E, Salomo S, Maier AM, Li-Ying J. Pharmaceutical new product development: why do clinical trials fail?: why do clinical trials fail? R D Manag. 2014;44(2):189–202.CrossRef

77.

Daniel GW, Cazé A, Romine MH, Audibert C, Leff JS, McClellan MB. Improving pharmaceutical innovation by building a more comprehensive database on drug development and use. Health Aff (Millwood). 2015;34(2):319–27.CrossRef

78.

de Villiers TJ. The quest for new drugs to prevent osteoporosis-related fractures. Climacteric. 2017;20(2):103–6.PubMedCrossRef

79.

von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. Promiscuous: a database for network-based drug-repositioning. Nucleic Acids Res. 2011;39(Database issue):D1060-6.CrossRef

80.

Empfield JR, Leeson PD. Lessons learned from candidate drug attrition. IDrugs. 2010;13(12):869–73.PubMed

81.

Feijoo F, Palopoli M, Bernstein J, Siddiqui S, Albright TE. Key indicators of phase transition for clinical trials through machine learning. Drug Discov Today. 2020;25(2):414–21.PubMedCrossRef

82.

Firn D. Roche drops trials of new HIV drug Pharmaceuticals: [London 1st Edition]. Financial Times. 2004;07:27.

83.

Friedhoff LT, Dailey J. Lost interest for existing compounds: new boosts. Eur Neuropsychopharmacol. 2015;25(7):1035–8.PubMedCrossRef

84.

Giannuzzi V, Landi A, Bosone E, Giannuzzi F, Nicotri S, Torrent-Farnell J, et al. Failures to further developing orphan medicinal products after designation granted in Europe: an analysis of marketing authorisation failures and abandoned drugs. BMJ Open. 2017;7(9): e017358.PubMedPubMedCentralCrossRef

85.

Cortez F, Griffin R. Biogen Surges as Momentum for Alzheimer’s Treatment Revives Hope. Bloomberg. Bloomberg.com. 2019.

86.

Gunther M. Big pharma opens up abandoned drugs [Internet]. Chemistryworld.com. Chemistry World; 2014. Cited 21 Aug 2021. Available from: https://www.chemistryworld.com/news/big-pharma-opens-up-abandoned-drugs/8064.article.

87.

Guo S-W, Groothuis PG. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? Hum Reprod Update. 2018;24(5):577–98.PubMedCrossRef

88.

Heltzer NE. Government cancels testing of HIV vaccine, Roche to suspend HIV research, new TB drug resistance test, topical estrogen protects men. The AIDS reader. 2008;18:396.

89.

Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med. 2016;176(12):1826–33.PubMedCrossRef

90.

Ismail HM, Dorchies OM, Scapozza L. The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. Expert Opin Orphan Drugs. 2018;6(4):259–71.CrossRef

91.

Jin G, Wong STC. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today. 2014;19(5):637–44.PubMedCrossRef

92.

Johannes L. Medicines Co. Gets Federal Approval Of Blood-Clot Drug. Wall Street Journal (1923 - Current file). ProQuest Historical Newspapers. 2000;B9.

93.

Kadioglu O, Efferth T. Contributions from emerging transcriptomics technologies and computational strategies for drug discovery. Invest New Drugs. 2014;32(6):1316–9.PubMedCrossRef

94.

Kerrigan SW. Repurposing old ways of treating sepsis. Irish Medical Times. 2018;11(32):33.

95.

Khanna R, Guler I, Nerkar A. Entangled decisions: Knowledge interdependencies and terminations of patented inventions in the pharmaceutical industry. Strategic Manage J. 2018;39(9):2439–65.CrossRef

96.

Kresge N, Bloomfield D. Why Big Pharma Is Willing to Lose Fortune Seeking Alzheimer Cure. Bloomberg. Bloomberg.com. 2017.

97.

Lotharius J, Gamo-Benito F, Angulo-Barturen I, Clark J, Connelly M, Ferrer-Bazaga S, et al. Repositioning: the fast track to new anti-malarial medicines? Malar J. 2014;13(1):143.PubMedPubMedCentralCrossRef

98.

Marrs ECL, Varadi L, Bedernjak AF, Day KM, Gray M, Jones AL, et al. Phosphonopeptides revisited, in an era of increasing antimicrobial resistance. Molecules. 2020;25(6):1445.PubMedCentralCrossRef

99.

Mehta D, Jackson R, Paul G, Shi J, Sabbagh M. Why do trials for Alzheimer’s disease drugs keep failing? a discontinued drug perspective for 2010–2015. Expert Opin Investig Drugs. 2017;26(6):735–9.PubMedPubMedCentralCrossRef

100.

Millan MJ, Goodwin GM, Meyer-Lindenberg A, Ove ÖS. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. Eur Neuropsychopharmacol. 2015;25(5):599–656.PubMedCrossRef

101.

Opar A. Mixed results for disease-modification strategies for Alzheimer’s disease. Nat Rev Drug Discov. 2008;7(9):717–8.PubMedCrossRef

102.

Ortuso F, Bagetta D, Maruca A, Talarico C, Bolognesi ML, Haider N, et al. The mu.Ta.Lig. Chemotheca: A community-populated molecular database for multi-target ligands identification and compound-repurposing. Front Chem. 2018;6. Available from: https://doi.org/10.3389/fchem.2018.00130.

103.

Parasrampuria DA, Benet LZ, Sharma A. Why drugs fail in late stages of development: case study analyses from the last decade and recommendations. AAPS J. 2018;20(3):46.PubMedCrossRef

104.

Pizzorno A. Fighting the Damocles Sword of Infectious Diseases Through Drug Repurposing. European Biopharmaceutical Review. 2019 winter.

105.

Plumridge H. Drug makers tiptoe back into antibiotic R&D. Wall Street journal (Eastern ed). 2014. Cited 21 Aug 2021. Available from: https://www.wsj.com/articles/drug-makers-tiptoe-back-into-antibiotic-rampd-1390512585.

106.

Pulley JM, Rhoads JP, Jerome RN, Challa AP, Erreger KB, Joly MM, et al. Using what we already have: uncovering new drug repurposing strategies in existing omics data. Annu Rev Pharmacol Toxicol. 2020;60(1):333–52.PubMedCrossRef

107.

Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, et al. Accelerating precision drug development and drug repurposing by leveraging human genetics. Assay Drug Dev Technol. 2017;15(3):113–9.PubMedPubMedCentralCrossRef

108.

Rowland C. Firms abandoning antibiotics research. Knight Ridder Tribune Business News. 2004;13:1.

109.

Saito H, Sumikura K. 2016 Drug development abandonment stage for Japanese pharmaceutical companies. 2016 Portland International Conference on Management of Engineering and Technology (PICMET). IEEE; 2016.

110.

Schwartz H. AIDS research: Who drives the train? Pharmaceutical Executive. 1995;15(7):22.

111.

Sekhon BS. Repositioning drugs and biologics: Retargeting old/existing drugs for potential new therapeutic applications. Journal of Pharmaceutical Education and Research. 2013;4(1).

112.

Silber J. Emeryville, Calif.-Based Biotechnology Firm Dampens Forecast for Profit. Knight Ridder Tribune Business News. 2002:1.

113.

Simons J. Big pharma’s new r&d center: the trash bin. Fortune magazine. 2006;154(12).

114.

Southall NT. Freedom of information act access to an investigational new drug application. ACS Pharmacol Transl Sci. 2019;2(6):497–500.PubMedPubMedCentralCrossRef

115.

Swiatek J. Eli Lilly to revisit its drug scrap bin. McClatchy - Tribune Business News. 2006;1.

116.

Townsend MJ, Arron JR. Reducing the risk of failure: biomarker-guided trial design. Nat Rev Drug Discov. 2016;15(8):517–8.PubMedCrossRef

117.

van Wijk RG. Positive and negative AIT trials: What makes the difference? Allergo J. 2018;27(6):36–41.CrossRef

118.

Verhaar AP, Wildenberg ME, Peppelenbosch MP, Hommes DW, van den Brink GR. Repurposing miltefosine for the treatment of immune-mediated disease? J Pharmacol Exp Ther. 2014;350(2):189–95.PubMedCrossRef

119.

NIH Initiative To Encourage Researchers To Find New Uses for Experimental Drugs. American Health Line. First Look 2012 May 04.

120.

Scientists aim to repurpose former experimental cancer therapy to treat muscular dystrophy. PharmaBiz. 2017.

121.

GSK Will Reveal More Drug Information From Clinical Trials. American Health Line. First Look 2012 Oct 11.

122.

AstraZeneca Business Briefs-Medical. Investor's Business Daily. 2012.

123.

New Dangers Seen In Pfizer’s Abandoned Experimental Heart Drug. FinancialWire. 2007;1

124.

Biogen stock plunges after company halts Alzheimer’s trials. MondayMorning. 2019;27(11).

Title: Drug repurposing: a systematic review on root causes, barriers and facilitators
Authors: Nithya Krishnamurthy
Alyssa A. Grimshaw
Sydney A. Axson
Sung Hee Choe
Jennifer E. Miller
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: BMC Health Services Research / Issue 1/2022
Electronic ISSN: 1472-6963
DOI: https://doi.org/10.1186/s12913-022-08272-z

2024 ASCO Annual Meeting

Springer Medicine

Drug repurposing: a systematic review on root causes, barriers and facilitators

Abstract

Background

Method

Results

Conclusion

Trial registration

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

Exploring the working environment of Hospital Managers: a mixed methods study investigating stress, stereotypes, psychological safety and individual resilience

Patient safety measurement tools used in nursing homes: a systematic literature review

The design of an evaluation framework for diabetes self-management education and support programs delivered nationally

Two decades of regional trends in vaccination completion and coverage among children aged 12-23 months: an analysis of the Uganda Demographic Health Survey data from 1995 to 2016

A longitudinal assessment of chronic care pathways in real-life: self-care and outcomes of chronic heart failure patients in Tuscany

Evaluating the impact of a training program to support transitioning from the hospital to the community for people after stroke: a community case study